17 Jul, 2024 FDA Will Now Regulate Laboratory Developed Tests By Darri Scalzo On April 29, 2024, the Food and Drug Administration (FDA) announced a final rule to consider laboratory-developed tests (LDTs) to be...
09 Jul, 2024 Political Nexus in Indian Startups: Essential Checks for Investors By Amit Jaju As the Indian startup ecosystem continues to thrive, attracting substantial investments from around the globe, investors are increasingly...
07 Jun, 2024 Are You Paying Attention to Prior Authorization? Your Regulators Are. By Jeffrey Low Dorothy DeAngelis Kelli Howe Richard Merino Angela Sabbe +2 more... Show less With recent CMS mandates and state-level reforms, the healthcare industry faces a pivotal moment to improve prior authorization...
22 Mar, 2024 When the Stakes Are High: Managing a Crisis-Led Investigation From Incident to Remediation By Lorynn Demetriades Alecia Futerman An investigative journalist implicates the company. An auditor threatens to resign. Premises are raided by enforcement agencies. Not all...
11 Mar, 2024 The Focus of Federal Proposals on Pharmacy Benefit Management – 118th Congress By Jeffrey Low Over the past several years, legislators across the country have focused their attention on Pharmacy Benefit Managers (PBMs) due to...
27 Nov, 2023 The Current Economic Climate - A Golden Age for Fraud? By Felix Vetter This article is the first of a series on accounting fraud which follows our July[1] and September webinars[2] on “How to Commit...
29 Mar, 2023 Understanding the Impact of the Economic Crime and Corporate Transparency Bill on Companies’ Risk Exposure By Sasi-Kanth Mallela Reecha Patel There has been a lot written about the potential impact of this bill when it becomes law. It could create new corporate offenses,...
22 Mar, 2023 Recent DOJ Updates to Corporate Compliance Program Expectations and Monitorship Appointments By Ankura Consulting In early March, Deputy Attorney General (DAG) Lisa Monaco and Assistant Attorney General (AAG) Kenneth A. Polite Jr. spoke in Miami to...
01 Mar, 2023 The Department of Justice’s Withdrawal of Three Antitrust Statements and the Impact on Health Care Organizations By Ankura On February 3, 2023, the Department of Justice Antitrust Division (DOJ) announced the withdrawal of three policy statements that have...
17 Feb, 2023 Assessing Your Bribery and Corruption Risk Exposure By Lorynn Demetriades There is no time like the present to refresh your organization’s bribery and corruption risk assessment. Many organizations recognized...
16 Dec, 2022 Trends in CCPA Enforcement from 2021 to 2022 – Try Harder By David Manek Colleen Yushchak This is the third article in a three-part series whereby Ankura privacy experts analyzed the 40 examples of alleged non-compliance with...
07 Dec, 2022 California AG’s Examples of CCPA Non-Compliance - Analysis of Targeted Industries By David Manek Colleen Yushchak This is the second article in a three-part series where Ankura privacy experts analyzed the 40 examples of non-compliance with the...